CA2 (Carbonic anhydrase 2) variants and mutations
CA2 (also known as Carbonic anhydrase 2) is a human protein-coding gene encoding a carbonic anhydrase 2 protein. It rapidly interconverts carbon dioxide and bicarbonate, supporting acid-base balance, renal acidification, respiration, bone remodeling, and fluid secretion. Biallelic loss-of-function variants cause carbonic anhydrase II deficiency, with osteopetrosis, renal tubular acidosis, and cerebral calcification. This analysis covers 455 CA2 variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes Osteopetrosis with renal tubular acidosis, autosomal recessive osteopetrosis 3, and glaucoma. Example CA2 variants include M1R, S2Y, and S2T.
Variant analysis overview
- Gene: CA2
- Protein: Carbonic anhydrase 2
- UniProt accession: P00918
- Organism: Homo sapiens
- Variants analyzed: 455
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 325 unspecified-consequence records; 70 missense variants; 40 synonymous variants; 10 frameshift variants; 3 splice-region variants; 3 stop-gained variants; 1 in-frame deletions; 4 substitution
- Prediction scores: 433 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Osteopetrosis with renal tubular acidosis, autosomal recessive osteopetrosis 3, glaucoma, epilepsy, ocular hypertension, open-angle glaucoma, Seizure, angle-closure glaucoma, altitude sickness, edema, migraine disorder, alcohol dependence.
Protein structure and variant hotspots
- Protein features: 1 domains; 4 binding sites; 4 post-translational modification sites.
- Structural context: 445 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CA2 variants
Examples include M1R, S2Y, S2T, S2S, H3Y, H3N, H3L, H3R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1R (p.Met1Arg), rs1811576779, ClinGen CA371422905, ClinVar RCV002274320, MetaLR 0.18, MetaSVM -0.74, Likely pathogenic, Neurodevelopmental delay
- S2Y (p.Ser2Tyr), gnomAD rs1304894123, REVEL 0.63, MetaLR 0.68, Uncertain significance, Osteopetrosis with renal tubular acidosis
- S2T (p.Ser2Thr), gnomAD 8-85464085-T-A, REVEL 0.17, MetaLR 0.44
- S2S (p.Ser2Ser), rs1353088995, gnomAD 8-85464087-C-A, CADD 14.70
- H3Y (p.His3Tyr), TOPMed rs1302977382, REVEL 0.31, MetaLR 0.52
- H3N (p.His3Asn), gnomAD 8-85464088-C-A, REVEL 0.40, MetaLR 0.53
- H3L (p.His3Leu), gnomAD 8-85464089-A-T, REVEL 0.37, MetaLR 0.37
- H3R (p.His3Arg), gnomAD 8-85464089-A-G, REVEL 0.25, MetaLR 0.48
- H3H (p.His3His), gnomAD 8-85464090-T-C, CADD 13.00
- H3Q (p.His3Gln), gnomAD 8-85464090-T-A, REVEL 0.19, MetaLR 0.39
- H4D (p.His4Asp), gnomAD rs1241095682, REVEL 0.23, MetaLR 0.35
- H4Y (p.His4Tyr), gnomAD 8-85464091-C-T, REVEL 0.31, MetaLR 0.53
- H4N (p.His4Asn), gnomAD 8-85464091-C-A, REVEL 0.19, MetaLR 0.46
- H4R (p.His4Arg), gnomAD 8-85464092-A-G, REVEL 0.19, MetaLR 0.43
- H4H (p.His4His), rs989228844, gnomAD 8-85464093-C-T, CADD 14.70
- H4Q (p.His4Gln), gnomAD 8-85464093-C-A, REVEL 0.22, MetaLR 0.50
- W5* (p.Trp5Ter), ESP rs372555587, TOPMed rs372555587, CADD 39.00
- W5C (p.Trp5Cys), ESP rs372555587, TOPMed rs372555587, REVEL 0.61, MetaLR 0.77
- W5L (p.Trp5Leu), gnomAD rs1489935449, REVEL 0.66, MetaLR 0.80
- W5R (p.Trp5Arg), Ensembl rs1184321968, REVEL 0.65, MetaLR 0.78
- G6E (p.Gly6Glu), rs769398095, ExAC rs769398095, gnomAD rs769398095, REVEL 0.79, MetaLR 0.77, Variant assessed as somatic; moderate impact.
- G6R (p.Gly6Arg), rs1219072767, ClinGen CA371423016, ClinVar RCV003020153, TOPMed rs1219072767, REVEL 0.80, MetaLR 0.79, Uncertain significance, not provided
- G6W (p.Gly6Trp), gnomAD 8-85464097-G-T, REVEL 0.85, MetaLR 0.87
- G6V (p.Gly6Val), gnomAD 8-85464098-G-T, REVEL 0.75, MetaLR 0.80
- G6G (p.Gly6Gly), gnomAD 8-85464099-G-T, CADD 9.00
- Y7* (p.Tyr7Ter), rs1554709677, ClinGen CA371423059, ClinVar RCV000625902, Ensembl rs1554709677, CADD 42.00, Pathogenic
- Y7T (p.Tyr7Thr), gnomAD 8-85464094-TG-T, CADD 32.00
- Y7V (p.Tyr7Val), gnomAD 8-85464094-T-TG, CADD 33.00
- Y7H (p.Tyr7His), gnomAD 8-85464100-T-C, REVEL 0.75, MetaLR 0.92
- Y7Y (p.Tyr7Tyr), gnomAD 8-85464102-C-T, CADD 14.90
- G8D (p.Gly8Asp), gnomAD rs1488758352, REVEL 0.12, MetaLR 0.24
- G8R (p.Gly8Arg), TOPMed rs1440181484, REVEL 0.37, MetaLR 0.48
- G8S (p.Gly8Ser), TOPMed rs1440181484, REVEL 0.15, MetaLR 0.36
- G8C (p.Gly8Cys), gnomAD 8-85464103-G-T, REVEL 0.38, MetaLR 0.51
- G8V (p.Gly8Val), gnomAD 8-85464104-G-T, REVEL 0.21, MetaLR 0.44
- G8A (p.Gly8Ala), gnomAD 8-85464104-G-C, REVEL 0.14, MetaLR 0.31
- G8G (p.Gly8Gly), gnomAD 8-85464105-C-T, CADD 15.80
- K9E (p.Lys9Glu), gnomAD 8-85464106-A-G, REVEL 0.13, MetaLR 0.09
- K9R (p.Lys9Arg), gnomAD 8-85464107-A-G, REVEL 0.04, MetaLR 0.22
- K9K (p.Lys9Lys), gnomAD 8-85464108-A-G, CADD 13.80
- H10P (p.His10Pro), 1000Genomes rs2130539869, REVEL 0.18, MetaLR 0.12
- H10Y (p.His10Tyr), rs1192862419, gnomAD rs1192862419, REVEL 0.07, MetaLR 0.19, Variant assessed as somatic; moderate impact.
- H10N (p.His10Asn), gnomAD 8-85464109-C-A, REVEL 0.06, MetaLR 0.11
- H10L (p.His10Leu), gnomAD 8-85464110-A-T, REVEL 0.10, MetaLR 0.14
- H10R (p.His10Arg), gnomAD 8-85464110-A-G, REVEL 0.10, MetaLR 0.15
- H10H (p.His10His), gnomAD 8-85464111-C-T, CADD 15.90
- H10Q (p.His10Gln), gnomAD 8-85464111-C-A, REVEL 0.04, MetaLR 0.12
- N11H (p.Asn11His), Ensembl rs893413258, MetaLR 0.21, MetaSVM -0.86
- N11K (p.Asn11Lys), gnomAD 8-85464114-C-A, REVEL 0.12, MetaLR 0.21
- N11N (p.Asn11Asn), rs1011782856, gnomAD 8-85464114-C-T, CADD 20.50
- G12E (p.Gly12Glu), ExAC rs748748151, TOPMed rs748748151, gnomAD rs748748151, REVEL 0.79, MetaLR 0.82, Uncertain significance, Osteopetrosis with renal tubular acidosis
- G12R (p.Gly12Arg), ExAC rs772898318, TOPMed rs772898318, gnomAD rs772898318, REVEL 0.92, MetaLR 0.85, Uncertain significance, not provided
- G12* (p.Gly12Ter), gnomAD 8-85464115-G-T, CADD 54.00
- G12V (p.Gly12Val), gnomAD 8-85465272-G-T, REVEL 0.77, MetaLR 0.87
- P13L (p.Pro13Leu), ExAC rs774046204, gnomAD rs774046204, REVEL 0.77, MetaLR 0.90
- P13S (p.Pro13Ser), gnomAD 8-85465274-C-T, REVEL 0.75, MetaLR 0.86
- E14G (p.Glu14Gly), Ensembl rs1811610212, MetaLR 0.25, MetaSVM -0.78
- E14K (p.Glu14Lys), rs758659684, ClinGen CA10631645, ClinVar RCV000369624, ClinVar RCV003168571, REVEL 0.10, MetaLR 0.22, Uncertain significance, Inborn genetic diseases; Osteopetrosis with renal tubular acidosis
- E14E (p.Glu14Glu), gnomAD 8-85465279-G-A, CADD 5.75
- E14D (p.Glu14Asp), gnomAD 8-85465279-G-C, REVEL 0.06, MetaLR 0.10
- H15Q (p.His15Gln), Ensembl rs1811610291, MetaLR 0.38, MetaSVM -0.67
- H15R (p.His15Arg), ExAC rs759148315, gnomAD rs759148315, REVEL 0.12, MetaLR 0.40
- W16* (p.Trp16Ter), Ensembl rs373969448, CADD 39.00
- W16C (p.Trp16Cys), NCI-TCGA TCGA novel, MetaLR 0.99, MetaSVM 0.97, Variant assessed as somatic; moderate impact.
- W16G (p.Trp16Gly), gnomAD 8-85465283-T-G, REVEL 0.96, MetaLR 0.99
- H17P (p.His17Pro), ExAC rs764493785, TOPMed rs764493785, gnomAD rs764493785, REVEL 0.31, MetaLR 0.17
- H17R (p.His17Arg), ExAC rs764493785, TOPMed rs764493785, gnomAD rs764493785, REVEL 0.21, MetaLR 0.19
- K18E (p.Lys18Glu), rs118203931, ClinGen CA114621, ClinVar RCV000000962, UniProt VAR 001380, REVEL 0.11, MetaLR 0.23, Pathogenic, CARBONIC ANHYDRASE II VARIANT
- K18Q (p.Lys18Gln), rs118203931, ClinGen CA4796404, ClinVar RCV002962174, 1000Genomes rs118203931, REVEL 0.10, MetaLR 0.42, Benign, not provided
- K18K (p.Lys18Lys), gnomAD 8-85465291-G-A, CADD 10.00
- D19N (p.Asp19Asn), TOPMed rs1443139589, gnomAD rs1443139589, REVEL 0.07, MetaLR 0.26
- F20L (p.Phe20Leu), rs1173459888, ClinGen CA371424282, ClinVar RCV003198056, TOPMed rs1173459888, REVEL 0.43, MetaLR 0.26, Uncertain significance, Inborn genetic diseases
- I22H (p.Ile22His), NCI-TCGA TCGA novel, MetaLR 0.37, MetaSVM -0.59, Variant assessed as somatic; high impact.
- I22T (p.Ile22Thr), gnomAD rs1400106377, REVEL 0.60, MetaLR 0.47
- I22F (p.Ile22Phe), gnomAD 8-85465301-A-T, REVEL 0.51, MetaLR 0.56
- I22V (p.Ile22Val), gnomAD 8-85465301-A-G, REVEL 0.23, MetaLR 0.31
- A23V (p.Ala23Val), Ensembl rs1811610769, REVEL 0.86, MetaLR 0.80
- K24E (p.Lys24Glu), Ensembl rs1811610821
- K24S (p.Lys24Ser), NCI-TCGA TCGA novel, MetaLR 0.17, MetaSVM -0.99, Variant assessed as somatic; high impact.
- G25E (p.Gly25Glu), rs1811610973, ClinGen CA371424383, ClinVar RCV001163654, Ensembl rs1811610973, AlphaMissense 0.81, MetaLR 0.90, Uncertain significance, Osteopetrosis with renal tubular acidosis
- G25R (p.Gly25Arg), rs762201348, ExAC rs762201348, gnomAD rs762201348, REVEL 0.83, MetaLR 0.91, Variant assessed as somatic; moderate impact.
- E26Q (p.Glu26Gln), gnomAD rs1334984459, REVEL 0.04, MetaLR 0.12
- E26E (p.Glu26Glu), rs1361076823, gnomAD 8-85465315-G-A, CADD 9.04
- R27C (p.Arg27Cys), TOPMed rs1380072010, gnomAD rs1380072010, REVEL 0.53, MetaLR 0.49
- R27G (p.Arg27Gly), TOPMed rs1380072010, gnomAD rs1380072010, REVEL 0.59, MetaLR 0.64
- R27H (p.Arg27His), rs765669662, NCI-TCGA Cosmic COSV5340, ExAC rs765669662, TOPMed rs765669662, REVEL 0.18, MetaLR 0.27, Variant assessed as somatic; moderate impact.
- R27L (p.Arg27Leu), ExAC rs765669662, TOPMed rs765669662, gnomAD rs765669662, REVEL 0.56, MetaLR 0.43
- R27R (p.Arg27Arg), gnomAD 8-85465318-C-T, CADD 8.81
- Q28P (p.Gln28Pro), rs1564077024, gnomAD 8-85465316-C-CG, CADD 31.00
- S29S (p.Ser29Ser), rs777914836, gnomAD 8-85465324-C-T, CADD 7.50
- P30S (p.Pro30Ser), gnomAD 8-85465325-C-T, REVEL 0.95, MetaLR 0.98
- P30L (p.Pro30Leu), gnomAD 8-85465326-C-T, REVEL 0.94, MetaLR 0.98
- V31A (p.Val31Ala), gnomAD 8-85465329-T-C, REVEL 0.56, MetaLR 0.80
- D32H (p.Asp32His), gnomAD rs1339603459, REVEL 0.67, MetaLR 0.79
- D32D (p.Asp32Asp), rs200305101, gnomAD 8-85465333-C-T, CADD 12.20
- I33L (p.Ile33Leu), ExAC rs751775209, gnomAD rs751775209, REVEL 0.66, MetaLR 0.72
- I33S (p.Ile33Ser), Ensembl rs1586010802, MetaLR 0.93, MetaSVM 1.08
- p.Ile33 Asp34del, gnomAD 8-85465330-TGACAT, CADD 20.60
- I33M (p.Ile33Met), gnomAD 8-85465335-TC-T, CADD 15.60
- I33I (p.Ile33Ile), rs755204118, gnomAD 8-85465336-C-T, CADD 5.28
- D34E (p.Asp34Glu), gnomAD rs201063453, REVEL 0.04, MetaLR 0.08, Uncertain significance, Osteopetrosis with renal tubular acidosis
- D34G (p.Asp34Gly), gnomAD 8-85465338-A-G, REVEL 0.10, MetaLR 0.24
- T35A (p.Thr35Ala), TOPMed rs1586010813, REVEL 0.27, MetaLR 0.22
- T35T (p.Thr35Thr), gnomAD 8-85465342-T-G, CADD 6.70
- H36P (p.His36Pro), ExAC rs781499832, gnomAD rs781499832, REVEL 0.11, MetaLR 0.15
- T37I (p.Thr37Ile), TOPMed rs1214017154, gnomAD rs1214017154, REVEL 0.10, MetaLR 0.18
- T37S (p.Thr37Ser), gnomAD rs1443776147, REVEL 0.03, MetaLR 0.11
- T37A (p.Thr37Ala), gnomAD 8-85465346-A-G, REVEL 0.03, MetaLR 0.11
- K39Q (p.Lys39Gln), rs2536478754, ClinGen CA371424597, ClinVar RCV002832860, Uncertain significance, not provided
- K39S (p.Lys39Ser), gnomAD 8-85465349-GC-G, CADD 22.80
- K39K (p.Lys39Lys), rs1811611845, gnomAD 8-85465354-G-A, CADD 9.41
- Y40* (p.Tyr40Ter), rs118203934, ClinGen CA114626, ClinVar RCV000000967, Ensembl rs118203934, Pathogenic
- Y40C (p.Tyr40Cys), gnomAD rs1262835490, REVEL 0.30, MetaLR 0.40
- Y40H (p.Tyr40His), TOPMed rs1376589900, gnomAD rs1376589900, REVEL 0.18, MetaLR 0.15
- Y40N (p.Tyr40Asn), NCI-TCGA TCGA novel, MetaLR 0.28, MetaSVM -0.67, Variant assessed as somatic; moderate impact.
- D41V (p.Asp41Val), TOPMed rs1811612056, gnomAD rs1811612056, REVEL 0.82, MetaLR 0.48
- D41Y (p.Asp41Tyr), gnomAD 8-85465358-G-T, REVEL 0.80, MetaLR 0.68
- D41D (p.Asp41Asp), gnomAD 8-85465360-C-T, CADD 9.18
- P42A (p.Pro42Ala), ExAC rs747884834, TOPMed rs747884834, gnomAD rs747884834, Uncertain significance
- P42H (p.Pro42His), gnomAD rs1811612182, REVEL 0.19, AlphaMissense 0.16, Uncertain significance, Inborn genetic diseases
- P42L (p.Pro42Leu), rs1811612182, ClinGen CA371424632, ClinVar RCV002608193, AlphaMissense 0.16, MetaLR 0.31, Uncertain significance, not provided
- P42T (p.Pro42Thr), rs747884834, ClinGen CA4796413, ClinVar RCV002626161, ClinVar RCV004065855, REVEL 0.11, MetaLR 0.22, Uncertain significance, Inborn genetic diseases; not provided
- S43P (p.Ser43Pro), gnomAD 8-85465364-T-C, REVEL 0.17, MetaLR 0.20
- S43F (p.Ser43Phe), gnomAD 8-85465365-C-T, REVEL 0.17, MetaLR 0.38
- S43S (p.Ser43Ser), rs1196409396, gnomAD 8-85465366-C-T, CADD 9.81
- K45E (p.Lys45Glu), NCI-TCGA Cosmic COSV5340, MetaLR 0.22, MetaSVM -0.82, Variant assessed as somatic; moderate impact.
- K45* (p.Lys45Ter), gnomAD 8-85465370-A-T, CADD 36.00
- P46S (p.Pro46Ser), NCI-TCGA Cosmic COSV5340, MetaLR 0.36, MetaSVM -0.38, Variant assessed as somatic; moderate impact.
- P46A (p.Pro46Ala), gnomAD 8-85465373-C-G, REVEL 0.31, MetaLR 0.26
- L47M (p.Leu47Met), 1000Genomes rs145096347, ESP rs145096347, ExAC rs145096347, TOPMed rs145096347, MetaLR 0.62, MetaSVM 0.27, Likely benign
- L47P (p.Leu47Pro), Ensembl rs1177461216, REVEL 0.85, MetaLR 0.64
- L47L (p.Leu47Leu), rs145096347, gnomAD 8-85465376-C-T, CADD 9.19
- S48C (p.Ser48Cys), ExAC rs777837845, TOPMed rs777837845, gnomAD rs777837845, REVEL 0.21, MetaLR 0.22
- S48Y (p.Ser48Tyr), NCI-TCGA Cosmic COSV5340, Variant assessed as somatic; moderate impact.
- S48F (p.Ser48Phe), rs1564077060, gnomAD 8-85465375-CCTGT-, CADD 28.10
- V49I (p.Val49Ile), Ensembl rs1811612616, MetaLR 0.08, MetaSVM -1.01
- V49V (p.Val49Val), rs747105608, gnomAD 8-85465384-T-C, CADD 2.10
- S50S (p.Ser50Ser), rs749302504, gnomAD 8-85465387-C-T, CADD 3.72
- Y51* (p.Tyr51Ter), rs1469283598, ClinGen CA371424682, ClinVar RCV003921471, CADD 32.00, Likely pathogenic
- Y51C (p.Tyr51Cys), ExAC rs745402787, gnomAD rs745402787, REVEL 0.69, MetaLR 0.87, Uncertain significance, Inborn genetic diseases; Osteopetrosis with renal tubular acidosis
- Y51H (p.Tyr51His), ExAC rs773780542, gnomAD rs773780542, REVEL 0.84, MetaLR 0.82
- Y51S (p.Tyr51Ser), ExAC rs745402787, gnomAD rs745402787, MetaLR 0.85, MetaSVM 0.96, Uncertain significance
- D52G (p.Asp52Gly), Ensembl rs2130543699, MetaLR 0.28, MetaSVM -0.66
- D52N (p.Asp52Asn), gnomAD 8-85465391-G-A, REVEL 0.31, MetaLR 0.27
- D52D (p.Asp52Asp), rs138896341, gnomAD 8-85465393-T-C, CADD 0.22
- Q53E (p.Gln53Glu), rs1811613004, ClinGen CA371424694, ClinVar RCV003733215, ClinVar RCV004374123, REVEL 0.09, MetaLR 0.13, Uncertain significance, not provided; Inborn genetic diseases
- Q53R (p.Gln53Arg), NCI-TCGA TCGA novel, TOPMed rs1811613054, gnomAD rs1811613054, REVEL 0.18, MetaLR 0.18, Variant assessed as somatic; moderate impact.
- Q53Q (p.Gln53Gln), rs1811613100, gnomAD 8-85465396-A-G, CADD 1.07
- A54E (p.Ala54Glu), ExAC rs762111570, gnomAD rs762111570, REVEL 0.08, MetaLR 0.20
- A54T (p.Ala54Thr), gnomAD 8-85465397-G-A, REVEL 0.04, MetaLR 0.13
- A54V (p.Ala54Val), gnomAD 8-85465398-C-T, REVEL 0.06, MetaLR 0.19
- T55N (p.Thr55Asn), gnomAD rs964579878, MetaLR 0.17, MetaSVM -0.96
- T55S (p.Thr55Ser), rs112536089, ClinGen CA180248611, ClinVar RCV002012234, Ensembl rs112536089, REVEL 0.10, MetaLR 0.12, Uncertain significance, not provided
- T55A (p.Thr55Ala), gnomAD 8-85465400-A-G, REVEL 0.11, MetaLR 0.14
- T55T (p.Thr55Thr), rs544987167, gnomAD 8-85465402-T-C, CADD 5.21
- S56F (p.Ser56Phe), gnomAD 8-85465404-C-T, REVEL 0.38, MetaLR 0.73
- S56S (p.Ser56Ser), gnomAD 8-85465405-C-T, CADD 0.18
- L57L (p.Leu57Leu), rs770204499, gnomAD 8-85465406-C-T, CADD 4.17
- R58R (p.Arg58Arg), rs773706393, gnomAD 8-85465411-G-A, CADD 7.30
- I59T (p.Ile59Thr), gnomAD rs1232519022, REVEL 0.74, MetaLR 0.65
- I59F (p.Ile59Phe), gnomAD 8-85465412-A-T, REVEL 0.58, MetaLR 0.43
- L60F (p.Leu60Phe), ESP rs374927018, ExAC rs374927018, gnomAD rs374927018, REVEL 0.13, MetaLR 0.16
- L60R (p.Leu60Arg), gnomAD 8-85465416-T-G, REVEL 0.21, MetaLR 0.20
- L60L (p.Leu60Leu), rs766461398, gnomAD 8-85465417-C-A, CADD 9.14
- N61S (p.Asn61Ser), TOPMed rs1485994749, gnomAD rs1485994749, REVEL 0.84, MetaLR 0.75
- N61N (p.Asn61Asn), rs923773110, gnomAD 8-85465420-C-T, CADD 9.23
- N62S (p.Asn62Ser), TOPMed rs1811613887, MetaLR 0.59, MetaSVM 0.08
- N62H (p.Asn62His), gnomAD 8-85465421-A-C, REVEL 0.89, MetaLR 0.83
- N62N (p.Asn62Asn), rs751545989, gnomAD 8-85465423-T-C, CADD 7.00
- G63C (p.Gly63Cys), NCI-TCGA TCGA novel, MetaLR 0.89, MetaSVM 1.08, Variant assessed as somatic; moderate impact.
- G63T (p.Gly63Thr), gnomAD 8-85465418-A-AACA, CADD 28.90
- G63V (p.Gly63Val), gnomAD 8-85465425-G-T, REVEL 0.96, MetaLR 0.84
- H64Q (p.His64Gln), NCI-TCGA TCGA novel, MetaLR 0.55, MetaSVM 0.06, Variant assessed as somatic; moderate impact.
- H64Y (p.His64Tyr), TOPMed rs1488441051, gnomAD rs1488441051, REVEL 0.63, MetaLR 0.32, Uncertain significance, Osteopetrosis with renal tubular acidosis
- H64L (p.His64Leu), gnomAD 8-85465428-A-T, REVEL 0.85, MetaLR 0.56
- H64H (p.His64His), rs759693878, gnomAD 8-85465429-T-C, CADD 10.40
- A65G (p.Ala65Gly), Ensembl rs1811614131, REVEL 0.29, MetaLR 0.38
- A65T (p.Ala65Thr), gnomAD 8-85465430-G-A, REVEL 0.17, MetaLR 0.13
- A65A (p.Ala65Ala), rs767577679, gnomAD 8-85465432-T-G, CADD 8.77
- F66V (p.Phe66Val), TOPMed rs1811614227, REVEL 0.37, MetaLR 0.12
Public CA2 analysis runs
- CA2 analysis run — CA2 (455 variants) — completed 2026-08-22